# Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

> **NCT04537689** · PHASE4 · RECRUITING · sponsor: **Singapore General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **BIOLOGICAL:** Ixekizumab
- **DRUG:** Methotrexate
- **DRUG:** Cyclosporin A
- **DRUG:** Acitretin

## Key facts

- **NCT ID:** NCT04537689
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537689, "Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04537689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*